Li Y - Search Results

1

Advances in endovascular therapy to treat primary hepatocellular carcinoma.

Guo Z, Yu H, Liu C, Si T, Yang X, Zhang W, Xu Y, Li Y. Guo Z, et al. Among authors: li y. Drug Discov Ther. 2015 Oct;9(5):342-51. doi: 10.5582/ddt.2015.01057. Drug Discov Ther. 2015. PMID: 26632543 Free article. Review.

2

MCM4 in human hepatocellular carcinoma: a potent prognostic factor associated with cell proliferation.

Xu Y, Yang X, Si T, Yu H, Li Y, Xing W, Guo Z. Xu Y, et al. Among authors: li y. Biosci Trends. 2021 May 11;15(2):100-106. doi: 10.5582/bst.2021.01016. Epub 2021 Mar 12. Biosci Trends. 2021. PMID: 33716256 Free article.

3

Clinicopathological and Prognostic Factors in 106 Prostate Cancer Patients Aged ≤55 Years: A Single-Center Study in China.

Xu Y, Yang X, Si T, Yu H, Zhang W, Li Y, Guo Z. Xu Y, et al. Among authors: li y. Med Sci Monit. 2016 Oct 23;22:3935-3942. doi: 10.12659/msm.901040. Med Sci Monit. 2016. PMID: 27771734 Free PMC article.

4

[A preliminary clinical study of targeted cryoablation of prostate in the treatment of T3N0M0 prostate cancer].

Guo Z, Wang HT, Xing WG, Liu F, Li Y, Yu HP. Guo Z, et al. Among authors: li y. Zhonghua Yi Xue Za Zhi. 2010 Nov 2;90(40):2815-9. Zhonghua Yi Xue Za Zhi. 2010. PMID: 21162789 Chinese.

5

[Clinical study of cryoablation in the salvage treatment of stage III non-small cell lung cancer].

Li Y, Guo Z, Wang HT, Liu F, Ni H. Li Y, et al. Zhonghua Yi Xue Za Zhi. 2011 Aug 23;91(31):2205-7. Zhonghua Yi Xue Za Zhi. 2011. PMID: 22094040 Chinese.

6

[Trend analysis of the incidence of prostate cancer in Tianjin between 1981 and 2004].

Song FJ, Zhang BL, He M, Li Y, Dong SF, Guo Z, Chen KX. Song FJ, et al. Among authors: li y. Zhonghua Yi Xue Za Zhi. 2010 Nov 2;90(40):2811-4. Zhonghua Yi Xue Za Zhi. 2010. PMID: 21162788 Chinese.

7

Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.

Li Y, Zheng YB, Zhao W, Liu B, Hu BS, He X, Huang JW, Lu LG. Li Y, et al. Med Oncol. 2013 Dec;30(4):730. doi: 10.1007/s12032-013-0730-5. Epub 2013 Sep 19. Med Oncol. 2013. PMID: 24048774

8

[Prognostic significance of serum level of vascular endothelial growth factor receptor-2 in hepatocellular carcinoma patients after transcatheter arterial chemoembolization].

Meng QW, Li Y, Hu BS, Shao PJ, Zhan MX, Yu XY, Lu LG. Meng QW, et al. Among authors: li y. Zhonghua Yi Xue Za Zhi. 2013 Jan 29;93(5):341-4. Zhonghua Yi Xue Za Zhi. 2013. PMID: 23660204 Chinese.

9

Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Zheng YB, Meng QW, Zhao W, Liu B, Huang JW, He X, Li Y, Hu BS, Lu LG. Zheng YB, et al. Among authors: li y. Med Oncol. 2014 Mar;31(3):843. doi: 10.1007/s12032-014-0843-5. Epub 2014 Jan 18. Med Oncol. 2014. PMID: 24442426

10

Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma.

Zheng YB, Huang JW, Zhan MX, Zhao W, Liu B, He X, Li Y, Hu BS, Lu LG. Zheng YB, et al. Among authors: li y. Tumour Biol. 2014 Nov;35(11):11473-81. doi: 10.1007/s13277-014-2478-8. Epub 2014 Aug 16. Tumour Biol. 2014. PMID: 25123269

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

235,654 results

Search Page

Filters